multiple myeloma;
central nervous system relapse;
clinical studies;
marizomib;
INVOLVEMENT;
D O I:
10.1111/bjh.14498
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed-refractory multiple myeloma (RRMM) and malignant glioma. Central nervous system-multiple myeloma (CNS-MM) is a rare manifestation of extra-medullary disease with few therapeutic options, highlighting the unmet clinical need in these patients. Marizomib demonstrated encouraging activity in RRMM and has emerging clinical activity in glioma, making it a potential CNS-MM therapeutic intervention. Herein, we present two patients with RRMM and CNS involvement who benefited from marizomib-based therapy. Thesecases provide the first proof of principle for further exploring marizomib in CNS-MM patients.